In the latest trading session, CVS Health (CVS) closed at $54.55, marking a +1.36% move from the previous day.
Investing in pharmacy chains hasn't been a good move in recent years. Rite Aid filed for (and emerged from) bankruptcy, and while its larger rivals aren't in as dire shape, they aren't exactly flourishing.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
CVS Health's poor 2024 performance was driven by negative macro and micro factors. Investors became too pessimistic about the company's forward prospects. A new CEO is a catalyst. Despite weak 2024 financial results, CVS is likely to begin to rebound in 2025. The company remains free cash flow positive, despite myriad challenges.
CVS Health (CVS) reachead $51.96 at the closing of the latest trading day, reflecting a -0.35% change compared to its last close.
As 2025 kicks off with a volatile start, many investors are likely feeling the pressure of heightened uncertainty. The S&P 500 and other major indices are down year-to-date, led by sharp declines in tech heavyweights like NVIDIA, which has fallen 13% from its 52-week high set just days ago.
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
As the largest MA plan sellers, UnitedHealth, Humana and CVS Health collectively account for nearly 60% of the market.
The CVS Health stock price rebounded to $48 on Monday, up 10% from its lowest in December. This rebound continued after the strong Walgreens Boots Alliance earnings, which pushed the stock up almost 50% from its lowest point in 2024.
Despite significant headwinds and a 43% stock decline, CVS Health's 5.8% dividend yield remains attractive, with a well-covered payout ratio of 55.9%. CVS faces strong competition from Amazon, Walmart, and Costco, impacting market share and pushing management to revise cash flow guidance down to $9.0 billion. The company saw double-digit revenue growth in two of its three segments, with a slight increase in pharmacy market share to 27.3%.
CVS Health (CVS 0.50%) is a stock that's been struggling badly for multiple years and is coming off a brutal performance in 2024, when its shares nose-dived by 43%.
CVS Health has been named as a Top 25 dividend stock, according the most recent Dividend Channel ''DividendRank'' report. The report noted that among the coverage universe, CVS shares displayed both attractive valuation metrics and strong profitability metrics.